Poster Presentations Session II
Poster Presentations Session II Monday, June 2, 2014
POSTERS SET-UP: 3:30 PM - 3:45 PM
POSTERS DISPLAY HOURS: 3:45 PM - 7:45 PM
POSTER AUTHOR DISCUSSION: 6:45 PM - 7:45 PM
POSTERS DISMANTLE: 7:45 PM


Poster display locations are shown below the poster codes
CANCER - Clinical Outcomes Studies
PCN1
A1
META-ANALYSIS OF ANASTOMOTIC LEAK RATES FOLLOWING HAND-SEWN SUTURE VERSUS STAPLED ANASTOMOSES DURING RIGHT COLON SURGERY
Roy S1, Ghosh SK2, Aggarwal S3, Yoo AC2
1Ethicon Surgical Care, Johnson & Johnson, Somerville, NJ, USA, 2Ethicon Surgical Care, Johnson & Johnson, Cincinnati, OH, USA, 3Novel Health Strategies, Bethesda, MD, USA

PCN2
A2
A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS (RCTS) ON EPIDERMAL GROWTH FACTOR RECEPTOR -TYROSINE KINASE INHIBITORS (EGFR-TKIS) FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
Zhang T1, Xu J2, Ma J3, Cai S2, Wu C1, Liu Y4
1Sun Yat-sen University, Guangzhou, China, 2Jinan University, Guangzhou, China, 3Harvard Medical School, boston, MA, USA, 4Harvard School of Public Health, boston, MA, USA

PCN3
A3
THE IMPACT OF PRE-EXISTING CHRONIC CONDITIONS ON CANCER DIAGNOSIS, RECEIPT OF TREATMENT AND SURVIVAL AMONG MEDICARE BENEFICIARIES WITH COLORECTAL CANCER IN A RURAL POPULATION
Rane PB1, Madhavan S1, Sambamoorthi U1, Kalidindi S1, Kurian S2, Pan X1
1West Virginia University School of Pharmacy, Morgantown, WV, USA, 2West Virginia University School of Medicine, Morgantown, WV, USA

PCN4
A4
GEOGRAPHICALLY-WEIGHTED REGRESSION ANALYSIS OF LATE-STAGE PROSTATE CANCER INCIDENCE IN FLORIDA
Xiao H1, Goovaerts P2, Ali AA1, Adunlin G1, Tan F3, Gwede C4, Huang Y5
1Florida A&M University, Tallahassee, FL, USA, 2BioMedware, Inc., Ann Arbor, MI, USA, 3Indiana University-Purdue University, Indianapolis, IN, USA, 4Moffitt Cancer Center, Tampa, FL, USA, 5Florida Department of Health, Tallahassee, FL, USA

PCN5
A5
TEMPORAL AND GEOGRAPHIC VARIATIONS OF PROSTATE CANCER INCIDENCE AND MORTALITY IN FLORIDA
Xiao H1, Goovaerts P2, Adunlin G1, Ali AA1, Tan F3, Gwede C4, Huang Y5
1Florida A&M University, Tallahassee, FL, USA, 2BioMedware, Inc., Ann Arbor, MI, USA, 3Indiana University-Purdue University, Indianapolis, IN, USA, 4Moffitt Cancer Center, Tampa, FL, USA, 5Florida Department of Health, Tallahassee, FL, USA

PCN6
A6
OBESITY & CANCER ARE INDEPENDENTLY ASSOCIATED WITH INCREASED COMORBID RISK IN DISTINCT 2013 DATA SOURCES: CLALIT ISRAEL EMR & U.S. NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)
Goren A1, Feldman B2, Hoshen M3, Rabi Y3, Philip EJ4, Brody J1, Witt EA5, Balicer RD3
1Kantar Health, New York, NY, USA, 2Clalit Research Institute, Tel Aviv, Israel, 3Clalit Health Services, Tel Aviv, Israel, 4Memorial Sloan-Kettering Cancer Center, New York, NY, USA, 5Kantar Health, Princeton, NJ, USA

PCN7
A7
AN ANALYSIS OF BIOMARKER TESTING AND APPROPRIATE TREATMENT AMONG WOMEN WITH BREAST CANCER USING ONCOLOGY EMR DATA
Foley K1, Bizier R1, Hansen LG2
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Northwood, NH, USA

PCN8
A8
IS DEPRESSION RELATED TO UNDERUSE OF BREAST CANCER SCREENING?
Park C, Ma X, Lawson KA
The University of Texas at Austin, Austin, TX, USA

PCN9
A9
COMPLEX SCREENING TEST FOR EARLY CANCER DIAGNOSTICS
Blavatska O
Danylo Halytskyj Lviv National Medical University, Lviv, Ukraine

PCN10
A10
RELATIONSHIP BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN HORMONE RECEPTOR-NEGATIVE METASTATIC BREAST CANCER (MBC): A COMPARATIVE EFFECTIVENESS ANALYSIS USING LINKED CLAIMS, EMR, AND MORTALITY RECORDS
Schabert VF1, Chen YJ1, Sun K2, Wang Y1
1IMS Health, Alexandria, VA, USA, 2IMS Health, Plymouth Meeting, PA, USA

PCN11
A11
MAGNITUDE OF BENEFIT AND COSTS FOR RECENT SOLID TUMOR AGENTS
Binder G1, Milentijevic D2, Squier M1, Whiting S1, Brown G3, Renschler MF1
1Celgene Corporation, Summit, NJ, USA, 2Market Access Solutions, Raritan, NJ, USA, 3

PCN12
A12
TREATMENT PATTERNS AND OUTCOMES IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS TREATED IN A COMMUNITY ONCOLOGY SETTING
Cartwright TH1, PAN I2, Wen L3, Wadlow RC4, Rembert D5, Seal B6
1Mckesson Specialty Health, Ocala, FL, USA, 2Mckesson Specialty Health, Conroe, TX, USA, 3Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA, 4Mckesson Specialty Health, Fairfax, VA, USA, 5Mckesson Specialty Health, The Woodlands, TX, USA, 6Bayer HealthCare Pharmaceuticals, Inc., White House Station, NJ, USA

PCN13
A13
SIMULATION AND COMPARISON OF PROGRESSION-FREE SURVIVAL (PFS) AMONG PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) RECEIVING SEQUENTIAL THERAPY
Chouaid C1, Walzer S2, Lister J3, Gultyaev D3, Vergnenegre A4, de Marinis F5, Meng J3, de Castro J6, Crott R7, Kleman M8, Ngoh CA8
1Santé publique au cabinet, Creteil, France, 2MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, 3LASER Analytica, Loerrach, Germany, 4Hôpital du Cluzeau Centre Hospitalier Universitaire (CHU) de Limoges, Limoges, France, 5Istituto Europeo di Oncologia, Rome, Italy, 6Medical Oncology Unit, Department of Translational Oncology, Hospital Universitario La Paz, Madrid, Spain, 7Université catholique de Louvain, Louvain, Belgium, 8F. Hoffmann-La Roche, Basel, Switzerland

PCN14
A14
A PHARMACOECONOMIC APPRAISAL OF CABAZITAXEL VS. ABIRATERONE FOR THE SECOND-LINE TREATMENT OF PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATE CANCER (MHRPC) PROGRESSING AFTER THE TREATMENT WITH DOCETAXEL: A SYSTEMATIC REVIEW
Bektur C, Nurgozhin T
Nazarbayev University, The Center for Life Sciences, Astana, Kazakhstan

PCN15
A15
THE RELATIVE CLINICAL AND ECONOMIC VALUE OF IPILIMUMAB AS FIRST-LINE TREATMENT OF METASTATIC MELANOMA VERSUS OTHER ANTI-CANCER AGENTS FOR METASTATIC DISEASES
Abernethy AP1, Kotapati S2, Gilloteau I2, Karweit J3, Wolfe S3
1Duke University Medical Center, Durham, NC, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3IMS Consulting Group, New York, NY, USA

PCN16
A16
A COMPARISON OF TOXICITY AND SUPPORTIVE CARE USE BETWEEN FOUR CYTOTOXIC AGENTS USED IN THE MANAGEMENT OF METASTATIC BREAST CANCER (MBC))
Dranitsaris G1, Knoth RL2, Cox D2, Faria C2
1Augmentium Pharma Consulting, Toronto, ON, Canada, 2Eisai, Inc., Woodcliff Lake, NJ, USA

PCN17
B1
ROBOT-ASSISTED VERSUS CONVENTIONAL LAPAROSCOPIC SURGERY FOR RECTAL CANCER: A SYSTEMATIC REVIEW
Kim J, Lee S, Lim S, Lee N
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea

PCN18
B2
REAL-WORLD SAFETY AND EFFICACY OF NAB-PACLITAXEL IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) TREATED IN THE UNITED STATES: RESULTS FROM A HEALTH INSURANCE DATABASE
Patt D1, Liang C2, Li L2, Ko A3, Duval Fraser C3, Corzo D4, Enger C5
1McKesson Specialty Health (MSH)/US Oncology (USO), Austin, TX, USA, 2Optum, Waltham, MA, USA, 3Celgene Corporation, Berkeley Heights, NJ, USA, 4Celgene Corporation, Summit, NJ, USA, 5Optum, Ann Arbor, MI, USA

PCN19
B3
CLINICAL EFFECTIVENESS AND SAFETY OF ROBOT ASSISTED RADICAL PROSTATECTOMY VERSUS RADICAL PROSTATECTOMY: USING SYSTEMATIC REVIEW APPROACH
Lee N1, Lee S1, Kim J1, Son SK1, Seo H2, Park D1
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, 2Chosun University, Gwangju, South Korea

PCN20
B4
HAVE NEW THERAPIES CHANGED THE FACE OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER TREATMENT IN CANADA?
Koa H, Merali T, Ali A
Drug Intelligence Inc., Toronto, ON, Canada

PCN21
B5
EVOLVING TREATMENT PATTERNS IN METASTATIC MELANOMA IN CANADA
Koa H, Merali T, Ali A
Drug Intelligence Inc., Toronto, ON, Canada

PCN22
B6
THE EFFECT OF GROUNDBREAKING MEDICAL THERAPY ON THE INCIDENCE OF DISEASE: A CASE STUDY OF RITUXIMAB AND NON-HODGKIN'S LYMPHOMA
Rotella P1, Teltsch D1, Swain R1, Ishak KJ2, Reynolds MW1, Robinson Jr. D3
1Evidera, Lexington, MA, USA, 2Evidera, St-Laurent, QC, Canada, 3Janssen Global Services, Malvern, PA, USA

PCN23
B7
INVESTIGATING SURVIVAL ASSOCIATED WITH ANGIOTENSIN BLOCKADE AGENTS IN PATIENTS WITH PANCREATIC CANCER
Karagiannis T1, Keith SW2, Rabinowitz C2, Louis D3, Maio V2
1Jefferson School of Population Health, Philadelphia, PA, USA, 2Thomas Jefferson University, Philadelphia, PA, USA, 3Jefferson Medical College, Philadelphia, PA, USA

PCN24
B8
BURDEN AND TIMING OF FIRST AND SUBSEQUENT SKELETAL RELATED EVENTS (SRES) IN US ELDERLY MEN WITH METASTATIC PROSTATE CANCER (MPC)
Abdulhalim AM1, Hussain A2, Mullins CD1, Qian Y3, Arellano J3, Balakumaran A3, Onukwugha E1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland School of Medicine, Baltimore, MD, USA, 3Amgen Inc., Thousand Oaks, CA, USA

PCN25
B9
ESTIMATING YEARS OF LIFE LOST DUE TO ADVANCED MELANOMA IN 12 COUNTRIES
Thiam A1, Zhao Z2, Weaver R1, Quinn C1, Barber B3
1PRMA Consulting, Fleet, UK, 2Amgen Inc, Thousand Oaks, CA, USA, 3Amgen, Inc., Thousand Oaks, CA, USA

PCN26
B10
MAMMOGRAPHIC DENSITY IN ASSOCIATION WITH SMOKING STATUS AND SMOKING HISTORIES IN A SAMPLE OF POSTMENOPAUSAL WOMEN: RESULTS FROM A CROSS-SECTIONAL STUDY
Majercak K1, Nghiem E2, Byrne C3, Muti P4, Barba M5, Lavigne J6, Faupel-Badger J6, Teter B7, Fuhrman B1
1University of Arkansas for Medical Sciences, Little Rock, AR, USA, 2University of Maryland, College Park, MD, USA, 3Uniformed Services University, Bethesda, MD, USA, 4McMaster University, Hamilton, ON, Canada, 5Italian National Cancer Institute, Rome, Italy, 6Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA, 7University of Buffalo, Buffalo, NY, USA

PCN27
B11
APPLYING DATA ANALYTICS TO VALUE-BASED CANCER CARE: EFFECTS AND COST OF HOSPITAL REENCOUNTERS FOLLOWING CANCER SURGERY
James T1, Jones C1, Lafrance D2, Nix ME2
1University of Vermont, Burlington, VT, USA, 2Fletcher Allen, Burlington, VT, USA

PCN28
B12
BEVACIZUMAB-BASED CHEMOTHERAPY AND THROMBOTIC EVENTS RISK IN COLORECTAL CANCER PATIENTS: A META-ANALYSIS STUDY OF RANDOMIZED CONTROLLED TRIALS
Alahmari AK, Guo JJ
University of Cincinnati College of Pharmacy, Cincinnati, OH, USA

PCN29
B13
ASSOCIATION BETWEEN CARDIOVASCULAR DRUGS AND COLON CANCER
Deshpande G1, Weiss S2, Polli J3, Shaya FT4, Zhan M5, Raufman J3
1HealthCore, Inc., Wilmington, DE, USA, 2DrugLogic, Reston, VA, USA, 3University of Maryland Baltimore, Baltimore, MD, USA, 4University of Maryland School of Pharmacy, Baltimore, MD, USA, 5University of Maryland School of Medicine, Baltimore, MD, USA

PCN30
B14
ASSOCIATION BETWEEN PIOGLITAZONE AND BLADDER CANCER AMONG PATIENTS WITH TYPE II DIABETES: A PROPENSITY SCORE MATCHED COHORT STUDY
Hsu YE1, Yang Y2, Chen P1, Yeh S3, Hsieh C4, Lin W5
1Taipei Medical University, Taipei, Taiwan, 2National Taiwan University, Taipei, Taiwan, 3Taipei Medical University Hospital, Taipei, Taiwan, 4Oriental Institute of Technology, Banciao City,Taipei County, Taiwan, 5Chang Jung Christian University, Tainan, Taiwan

PCN31
B15
NO EXCESS RISK OF MORTALITY IN LONG-TERM SURVIVORS OF ADVANCED MELANOMA
Heisen M1, Tempest MJ2, Majer IM1
1Pharmerit International, Rotterdam, The Netherlands, 2Pharmerit Ltd, York, UK

PCN32
B16
IMPACT ON ILLNESS-FREE SURVIVAL (IFS) AND GLOBAL SURVIVAL (GS) OF THE STARTING TIME OF ADJUVANT BREAST CANCER
Villalobos Valencia R1, Soto Molina H2, Díaz Martínez JP3, Victoria Ayala R4, Ayala Anzures M4, Ortiz Rodríguez K4, Valenzuela Martínez M4, Talamantes Gómez E4
1Centro Médico Nacional "La Raza", Mexico City, Mexico, 2Universidad Autónoma Metropolitana, Mexico City, Mexico, 3HS Estudios Farmacoeconómicos, Mexico City, Mexico, 4Centro Médico Nacional, Mexico City, Mexico

PCN33
C1
TREATMENT AND SURVIVAL PATTERNS AMONG ALK+ NSCLC PATIENTS FOLLOWING CRIZOTINIB DISCONTINUATION
Guerin A1, Wakelee H2, Sasane M3, Zhang J3, Galebach P4, Jarvis J4, Kageleiry A4, Huang Q4, Culver K3, Wu EQ4, Macalalad AR4
1Analysis Group, Inc., Montréal, QC, Canada, 2Stanford University School of Medicine, Palo Alto, CA, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Analysis Group, Inc., Boston, MA, USA

PCN34
WITHDRAWN

CANCER - Cost Studies
PCN35
C2
THE UTILIZATION OF VIDEO-ASSISTED THORACIC SURGERY (VATS) VERSUS OPEN THORACOTOMY FOR STAGE 1 AND STAGE 2 NON-SMALL CELL LUNG CANCER IN CANADIAN HOSPITALS: A BUDGET IMPACT ANALYSIS
Ondrejicka DA, Goldstein LJ
Johnson and Johnson Medical Companies, Markham, ON, Canada

PCN36
C3
ESTIMATING THE ECONOMIC IMPACT OF RADIUM RA 223 DICHLORIDE (RADIUM-223) IN TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE
Valderrama A1, Bilir SP2, Wehler EA3, Seal BS1, Wen L1, Yaldo A1, Munakata J2
1Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA, 2IMS Health, San Francisco, CA, USA, 3IMS Health, Alexandria, VA, USA

PCN37
C4
BUDGET IMPACT OF THE 14-GENE RISK-SCORE (RS) ASSAY TO INFORM ADJUVANT CHEMOTHERAPY DECISIONS IN EARLY-STAGE NON-SMALL CELL LUNG CANCER (NSCLC)
Roth JA1, Billings P2, Ramsey S3, Dumanois R2, Carlson JJ4
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2Life Technologies, Inc, Carlsbad, CA, USA, 3Fred Hutchinson Cancer Research Center and Professor, Department of Medicine, University of Washington, Seattle, WA, USA, 4University of Washington, Seattle, WA, USA

PCN38
WITHDRAWN

PCN39
C5
BUDGETARY IMPACT OF ORAL CHEMOTHERAPY IN BRAZIL: A REAL WORLD DATA ANALYSIS FROM THE PRIVATE PAYERS' PERSPECTIVE
Clark OA1, Castro AP2, Alves AF2, Goes L3, Borges L2
1Evidencias, Campinas, Brazil, 2Evidências, Campinas, Brazil, 3Evidências Credibilidade Científica, Campinas, Brazil

PCN40
C6
BUDGET IMPACT OF ALBUMIN-BOUND PACLITAXEL + GEMCITABINE IN THE TREATMENT OF METASTATIC PANCREATIC CANCER
Binder G1, Whiting S1, Milentijevic D2, Penenberg D3, Wei X3, Kayitalire L1, Renschler MF1
1Celgene Corporation, Summit, NJ, USA, 2Market Access Solutions, Raritan, NJ, USA, 3Celgene Corporation, Berkeley Heights, NJ, USA

PCN41
C7
BURDEN OF DISEASE ATTRIBUTABLE TO SMOKING IN COLOMBIA
Peña-Torres E1, Osorio-Cuevas DI1, Gamboa-Garay O2, Pichón-Riviere A3, Bardach A4, Alcaraz A5, Caporale J5, Augustovski F6
1Instituto de Evaluación Tecnológica en Salud, Bogotá, Colombia, 2Instituto Nacional de Cancerología, Bogotá, Colombia, 3Instituto de Efectividad Clínica y Sanitaria, Buenos Aires, Argentina, 4Institute for Clinical Effectiveness and Health Policy (IECS), CABA, Buenos Aires, Argentina, 5Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, 6Family and Community Medicine Division, Italian Hospital of Buenos Aires, Buenos Aires, Argentina

PCN42
C8
BUDGET IMPACT ANALYSIS OF BEVACIZUMAB AND ANTI-EGFR WITH CHEMOTHERAPY FOR FIRST AND SECOND LINE TREATMENT OF METASTATIC COLORECTAL CANCER IN RUSSIAN FEDERATION
Yagudina R, Kulikov A, Komarov I
I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PCN43
C9
BUDGET IMPACT ANALYSIS FOR NILOTINIB USE IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN COLOMBIA
Romero M, Acero G, Marrugo R
Fundacion Salutia, Bogota, Colombia

PCN44
C10
BUDGET IMPACT ANALYSIS OF CRIZOTINIB AS TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK) POSITIVE ADVANCED NSCLC IN PANAMA
Garita M1, Peralta M1, Lopez RI2
1Pfizer Central America and Caribbean, Escazu, San Jose, Costa Rica, 2Instituto Oncologico Nacional, Cuidad de Panama, Panama

PCN45
C11
A BUDGET IMPACT MODEL FOR THE INTRODUCTION OF BEVACIZUMAB FOR THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN THE UK
Scola A1, Lock K2, Ngoh CA3
1McCann Complete Medical, Macclesfield, UK, 2Roche Products Limited, Welwyn Garden City, UK, 3F. Hoffmann-La Roche, Basel, Switzerland

PCN46
C12
BUDGET IMPACT ANALYSIS OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS BEVACIZUMAB AND ANTI-EGFR WITH CHEMOTHERAPY FOR FIRST AND SECOND LINE TREATMENT OF METASTATIC COLORECTAL CANCER IN RUSSIAN FEDERATION
Yagudina R, Kulikov A, Komarov I
I.M. Sechenov First Moscow State Medical University, Moscow, Russia

PCN47
C13
PROJECTED CLINICAL, RESOURCE, AND BUDGET IMPACT OF IMPLEMENTING LOW-DOSE COMPUTED TOMOGRAPHY LUNG CANCER SCREENING IN THE UNITED STATES
Roth JA1, Sullivan SD2, Ravelo A3, Sanderson JC2, Ramsey S1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA, 3Genentech, Inc, South San Francisco, CA, USA

PCN48
C14
COST ANALYSIS OF ADVERSE EVENTS ASSOCIATED WITH FIRST LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA (MRCC) IN THE PERSPECTIVE OF PUBLIC AND PRIVATE HEALTH INSURANCE IN BRAZIL
Ferreira CN, Rufino CS, Manfrin DF
Pfizer, Inc., São Paulo, Brazil

PCN49
C15
EVALUATING COSTS AND UTILIZATION OF PROSTATE CANCER PATIENTS WITH BONE METASTASES IN THE OUTPATIENT HOSPITAL SETTING
Seal BS1, Zagadailov E2, Farrelly E2, Asche C3, Germino R4, Rietschel P4, Eaddy M2, Stafkey-Mailey D2
1Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, 2Xcenda, Palm Harbor, FL, USA, 3University of Illinois, Peoria, IL, USA, 4Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA

PCN50
C16
CLINICAL OUTCOMES AND BUDGET IMPACT OF COBAS® EGFR MUTATION TEST VERSUS SANGER SEQUENCING IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NSCLC: A US PAYER PERSPECTIVE
Poulios N1, Hertz D2, Gavaghan M2
1Roche Molecular Diagnostics, Pleasanton, CA, USA, 2GfK Market Access, Wayland, MA, USA

PCN51
D1
A CANADIAN COST IMPACT ANALYSIS COMPARING MAINTENANCE THERAPY WITH BORTEZOMIB VERSUS LENALIDOMIDE IN MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR STEM CELL TRANSPLANT
Shustik J1, Tay J2, Hollmann S3, LeBlanc R4
1Fraser Valley Cancer Centre, Surrey, BC, Canada, 2Ottawa Hospital, Ottawa, ON, Canada, 3Cornerstone Research Group, Burlington, ON, Canada, 4Maisonneuve-Rosemont Hospital, Montreal, QC, Canada

PCN52
D2
CLINICAL AND ECONOMIC BURDEN ASSOCIATED WITH ANASTOMOTIC LEAK AFTER COLORECTAL SURGERIES IN THE UNITED KINGDOM
Wan Y1, Lim S2, Riebman J2, Jamous N3, Gao X1
1Pharmerit International, Bethesda, MD, USA, 2Ethicon, Inc, Somerville, NJ, USA, 3Ethicon Inc., Wokingham, UK

PCN53
D3
TOTAL TREATMENT COSTS ANALYSIS BETWEEN SUBCUTANEOUS AND INTRAVENOUS BORTEZOMIB UNDER BRAZILIAN PRIVATE HEALTH CARE SYSTEM PERSPECTIVE
Vitale V1, Pinto Neto JV2, Asano E1
1Janssen-Cilag Farmaceutica, São Paulo, Brazil, 2Hospital de Base de Brasília, Brasília, Brazil

PCN54
D4
A CANADIAN COST ANALYSIS COMPARING THE USE OF BORTEZOMIB OR LENALIDOMIDE AS MAINTENANCE THERAPIES IN MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
LeBlanc R1, Tay J2, Hollmann S3, Shustik J4
1Maisonneuve-Rosemont Hospital, Montreal, QC, Canada, 2Ottawa Hospital, Ottawa, ON, Canada, 3Cornerstone Research Group, Burlington, ON, Canada, 4Fraser Valley Cancer Centre, Surrey, BC, Canada

PCN55
D5
THE HEALTH ECONOMIC IMPACT OF COFFEE CONSUMPTION ON PREVENTION OF CHRONIC DISEASE AND CANCER IN THE UNITED STATES
O'Day K1, Campbell CM1, Popelar BV1, McLaughlin T2
1Xcenda, LLC, Palm Harbor, FL, USA, 2Xcenda, Palm Harbor, FL, USA

PCN56
D6
EXCESS HEALTHCARE COSTS AMONG ELDERLY BREAST CANCER PATIENTS, BY RECEIPT OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-TARGETED THERAPY: AN ANALYSIS OF SEER-MEDICARE DATA
Hao Y1, Lang K2, Huang H2, Lin I2, Rogerio JW1, Menzin J2
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2Boston Health Economics, Inc., Waltham, MA, USA

PCN57
D7
COSTS ASSOCIATED WITH HEALTHCARE RESOURCE USE IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE TREATMENT WITH PAZOPANIB VERSUS SUNITINIB
Hackshaw MD1, Hansen RN2, Nagar SP1, Arondekar B1, Deen KC1, Sullivan SD3, Ramsey SD4
1GlaxoSmithKline, Phialdelphia, PA, USA, 2School of Pharmacy, University of Washington, Seattle, WA, USA, 3University of Washington, Seattle, WA, USA, 4Fred Hutchinson Cancer Research Center and Professor, Department of Medicine, University of Washington, Seattle, WA, USA

PCN58
D8
COST COMPARISON OF DIFFERENT FORMS OF ANDROGEN ABLATIVE THERAPIES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CANADA
Dragomir A, Vanhuyse M, Aprikian A
McGill University, Montreal, QC, Canada

PCN59
D9
MEDICAL COSTS BY DISEASE STAGE IN MEDICARE PATIENTS WITH MELANOMA
Farr AM1, Zhao Z2, Song X3, Barber BL2, Ivanov B1
1Truven Health Analytics Inc, Cambridge, MA, USA, 2Amgen Inc, Thousand Oaks, CA, USA, 3Truven Health Analytics, Cambridge, MA, USA

PCN60
D10
INCREMENTAL BURDEN OF ANASTOMOTIC LEAKS IN COLORECTAL SURGERIES
Ghosh SK1, Roy S1, Ryan MP2, Gunnarsson C2, Yoo AC1
1Ethicon Surgical Care, Johnson & Johnson, Cincinnati, OH, USA, 2S2 Statistical Solutions, Inc., Cincinnati, OH, USA

PCN61
D11
HEALTHCARE BURDEN ASSOCIATED WITH BREAST CANCER IN THE MEDICAID POPULATION
Mahabaleshwarkar R1, Khanna R1, Banahan BF1, West-Strum D1, Yang Y1, Hallam J2
1University of Mississippi, University, MS, USA, 2Kent State University, Kent, OH, USA

PCN62
D12
COST PROFILE OF PATIENTS WITH GASTRIC CANCER USING US ADMINISTRATIVE CLAIMS DATA
Hirst C1, Ryan J1, Tunceli O2, Wu B2, Kern DM2
1AstraZeneca, Macclesfield, UK, 2HealthCore, Inc., Wilmington, DE, USA

PCN63
D13
INCREASING BURDEN OF TYROSINE KINASE INHIBITOR (TKI) TREATMENT FAILURE WITH LATER LINES OF THERAPY (LOT) IN CHRONIC MYELOID LEUKEMIA (CML): A REAL WORLD RETROSPECTIVE DATABASE ANALYSIS
Chen YJ1, Huang H2, Divino V1, Pokras SM1, Hallinan S1, Munakata J3, Taylor C2, McGarry L2, Ng D2, Nieset C2, Malone D4
1IMS Health, Alexandria, VA, USA, 2ARIAD Pharmaceuticals, Cambridge, MA, USA, 3IMS Health, San Francisco, CA, USA, 4University of Arizona, Tucson, AZ, USA

PCN64
D14
COST OF BREAST CANCER IN VIETNAM
Nguyen TT1, Nguyen VH2
1University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Vietnam, 2University of Medicine and Pharmacy in HCMC, HCMC, Vietnam

PCN65
D15
EVALUATE THE ECONOMIC BURDEN OF NON SMALL CELL LUNG CANCER IN VIETNAM
Nguyen TT1, Dinh HT2
1University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Vietnam, 2University of Medicine and Pharmacy in HCMC, HCMC, Vietnam

PCN66
WITHDRAWN

PCN67
D16
ECONOMIC BURDEN AND HEALTH CARE UTILIZATIONS OF U.S. MEDICARE PATIENTS DIAGNOSED WITH PROSTATE CANCER
Wang L1, Xie L2, Li L1, Wang Y2, Kariburyo MF2, Baser O3
1STATinMED Research, Plano, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 3STATinMED Research and The University of Michigan, Ann Arbor, MI, USA

PCN68
E1
ECONOMIC COST OF ADVERSE EVENTS PER COURSE OF THERAPY WITH COMMONLY USED FIRST-LINE REGIMENS FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
Monberg MJ1, Shukla A2, Le HV3, Lin T4, Bonifacio G1
1GlaxoSmithKline, Philadelphia, PA, USA, 2GlaxoSmithKline, Upper Providence, PA, USA, 3GlaxoSmithKline, RTP, NC, USA, 4GlaxoSmithKline, Collegeville, PA, USA

PCN69
E2
HEALTH CARE RESOURCE UTILIZATION IN THE MANAGEMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA AT AN ONTARIO CANCER CENTRE
Mittmann N1, Hassan S1, Seung SJ1, Bannon G1, Cheung M1, Fraser G2, Fine S3, Kuriakose B4
1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2McMaster University- Juravinski Cancer Centre, Hamilton, ON, Canada, 3Credit Valley Hospital, Mississauga, ON, Canada, 4Janssen Inc, Toronto, ON, Canada

PCN70
E3
COST & RESOURCE UTILIZATION OF CERVICAL CANCER IN BRITISH COLUMBIA
Ferreira ZJ1, Cromwell I1, Smith L1, Peacock S2
1British Columbia Cancer Agency, Vancouver, BC, Canada, 2Canadian Centre for Applied Research in Cancer Control, Vancouver, BC, Canada

PCN71
E4
ECONOMIC BURDEN OF PROLONGED AIR LEAK AFTER LUNG RESECTION: OPEN VERSUS VIDEO-ASSISTED THORACOSCOPIC SURGERY (VATS)
Swanson S1, Miller D2, McKenna R3, Meyers B4, Marshall MB5, Ghosh SK6, Fegelman E7, Roy S8, Ryan M9, Gunnarsson C9, Howington JA10
1Brigham and Women's Hospital and the Dana Farber Cancer Institute, Old Greenwich, CT, USA, 2Emory University, Atlanta, GA, USA, 3Cedars-Sinai Medical Center, Los Angeles, CA, USA, 4Washington University, Creve Coeur, MO, USA, 5Georgetown University Medical Center, Washington DC, DC, USA, 6Ethicon Surgical Care, Johnson & Johnson, Cincinnati, OH, USA, 7Ethicon, Cincinnati, OH, USA, 8Johnson & Johnson Global Surgery Group, Somerville, NJ, USA, 9S2 Statistical Solutions, Inc., Cincinnati, OH, USA, 10NorthShore University HealthSystem, Evanston, IL, USA

PCN72
E5
COST ASSESSMENT OF ADVANCED OVARIAN CANCER TREATMENT IN A LARGE COHORT OF ELDERLY PATIENTS
Poonawalla IB1, Lairson DR2, Du XL2
1University of Texas Health Science Center Houston, School of Public Health, Dallas, TX, USA, 2University of Texas Health Science Center Houston, School of Public Health, Houston, TX, USA

PCN73
E6
DIRECT MEDICAL COSTS (DMC) OF TREATING PROSTATE CANCER IN A MEDICAL COOPERATIVE HMO IN BRAZIL: RESULTS FROM A LONGITUDINAL ANALYSIS OF AN ADMINISTRATIVE DATABASE
Santos MC, Luiz CB, Maturana MS
Unimed São José do Rio Preto, São José do Rio Preto, Brazil

PCN74
E7
ASSESSING THE ECONOMIC BURDEN OF ADVERSE EFFECTS (AES) ASSOCIATED WITH METASTATIC MELANOMA (MM) TREATMENTS IN GERMANY
Vouk K1, Amonkar M2, Benter U1
1INC Research GmbH, Munich, Germany, 2GlaxoSmithKline, Collegeville, PA, USA

PCN75
E8
FREQUENCY AND COSTS ASSOCIATED WITH TARGETED THERAPY-RELATED ADVERSE EVENTS (AES) DURING FIRST AND SECOND LINE OF TREATMENT (LOT) AMONG PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC)
DaCosta Byfield S1, Langer C2, Ogale S2, Morlock R2
1Optum, Eden Prairie, MN, USA, 2Genentech, South San Francisco, CA, USA

PCN76
E9
EARLY STAGE BREAST CANCER: VARIATIONS IN TOTAL AND CHEMOTHERAPY EXPENSES AMONG 10 MILLION COMMERCIALLY INSURED MEMBERS
Bowen KL, Gleason PP
Prime Therapeutics, Eagan, MN, USA

PCN77
E10
ECONOMIC BURDEN OF ADVERSE EFFECTS ASSOCIATED WITH METASTATIC MELANOMA (MM) TREATMENTS IN THE UNITED KINGDOM (UK)
Vouk K1, Benter U1, Amonkar M2, Stapelkamp C3
1INC Research GmbH, Munich, Germany, 2GlaxoSmithKline, Collegeville, PA, USA, 3GlaxoSmithKline, Uxbridge, UK

PCN78
E11
COST BURDEN OF ADVERSE EFFECTS ASSOCIATED WITH METASTATIC MELANOMA (MM) THERAPIES IN AUSTRALIA
Benter U1, Amonkar M2, Vouk K1
1INC Research GmbH, Munich, Germany, 2GlaxoSmithKline, Collegeville, PA, USA

PCN79
E12
LITERATURE REVIEW ON TOTAL MEDICAL COSTS AND COST COMPONENTS OF ONCOLOGY CARE IN THE US
Song X1, Brouillette M2, Gatta F3, Cristino J3, Arellano J4, Qian Y4
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Ann Arbor, MI, USA, 3Amgen (Europe) GmbH, Zug, Switzerland, 4Amgen Inc., Thousand Oaks, CA, USA

PCN80
E13
TRENDS IN APPROVALS AND PRICES OF ONCOLOGY DRUGS IN THE US (1990-2013)
Greene N1, Turkistani FA2, Seoane-Vazquez E3, Rodriguez-Monguio R4
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 2Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, USA, 3International Center for Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA, 4University of Massachusetts Amherst, Amherst, MA, USA

PCN81
E14
TREATMENT PATTERNS AND COST OF CARE FOR PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST) TREATED WITH IMATINIB
Seal BS1, Xia F2, Stafkey-Mailey D3, Asche C4, Zagadailov E3, Eaddy M3
1Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, 2Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA, 3Xcenda, Palm Harbor, FL, USA, 4University of Illinois, Peoria, IL, USA

PCN82
E15
HOSPITAL COSTS OF ADVERSE EVENTS IN PATIENTS WITH METASTATIC MELANOMA
Ma Q, Zhao Z, Barber BL
Amgen Inc, Thousand Oaks, CA, USA

PCN83
WITHDRAWN

PCN84
E16
HEALTH INSURER BURDEN OF PATIENT RECALL FOLLOWING BREAST CANCER SCREENING MAMMOGRAPHY
Bonafede MM1, Miller JD1, Lenhart GM1, Nelson J2, Fajardo LL3
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Bethesda, MD, USA, 3University of Iowa College of Medicine, Iowa City, IA, USA

PCN85
F1
A COST-EFFECTIVENESS ANALYSIS OF FIRST LINE INDUCTION AND MAINTENANCE TREATMENT SEQUENCES IN NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN THE U.S
Kumar G1, Woods B1, Winfree KB2, Boye ME2, Hess LM2, Bryden PA3, Koustenis A2, Treat J2
1ICON Health Economics, Oxford, UK, 2Eli Lilly and Company, Indianapolis, IN, USA, 3University of Bristol, Bristol, UK

PCN86
F2
ASSESSING THE POTENTIAL COST-EFFECTIVENESS OF ALTERNATIVE METHODS TO SCREEN FOR CERVICAL CANCER AMONG HIV-POSITIVE WOMEN IN KENYA
Mann M, Babigumira JB, Garrison LP, Chung M
University of Washington, Seattle, WA, USA

PCN87
F3
COST-EFFECTIVENESS ANALYSIS OF ABIRATERONE AND SIPULEUCEL-T IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Gong CL, Hay JW
University of Southern California, Los Angeles, CA, USA

PCN88
F4
A NOVEL COLORECTAL CANCER MODEL WITH SESSILE SERRATED ADENOMA PATHWAY TO EVALUATE THE COST-EFFECTIVENESS OF VARIOUS SCREENING STRATEGIES
Zheng P, Dinh T
Evidera, San Francisco, CA, USA

PCN89
F5
COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE-RITUXIMAB TREATMENT COMPARED WITH FLUDARABINE-RITUXIMAB TREATMENT, IN PATIENTS WITH INDOLENT NON-HODGKIN'S LYMPHOMA IN PANAMÁ
Desanvicente-Celis Z1, Obando CA2, Rodriguez E2, Gonzalez L3, Muschett D1
1Janssen, Panama, Panama, 2Janssen, Panama City, Panama, 3Janssen, Raritan, NJ, USA

PCN90
F6
COST EFFECTIVENESS OF TRAMETINIB AS FIRST-LINE (1L) TREATMENT FOR BRAF V600 POSITIVE ADVANCED OR METASTATIC MELANOMA — A CANADIAN SOCIETAL PERSPECTIVE
Amdahl J1, Wang A1, Thabane M2, Amonkar M3, Delea TE1
1Policy Analysis Inc. (PAI), Brookline, MA, USA, 2GlaxoSmithKline, Mississauga, ON, Canada, 3GlaxoSmithKline, Collegeville, PA, USA

PCN91
F7
COST-EFFECTIVENESS OF ARSENIC TRIOXIDE + ALL-TRANS RETINOIC ACID COMPARED WITH ALL-TRANS RETINOIC ACID + IDARUBICIN IN THE TREATMENT OF NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LYMPHOMA LEUKEMIA IN CANADA
Lachaine J1, Mathurin K1, Barakat S2
1University of Montreal, Montreal, QC, Canada, 2Lundbeck Canada, Montreal, QC, Canada

PCN92
F8
PARTIALLY COVERED SELF-EXPANDABLE METAL STENTS ARE MORE COST-EFFECTIVE WHEN COMPARED TO PLASTIC STENTS FOR PATIENTS WITH DISTAL MALIGNANT BILIARY OBSTRUCTION
Adam V1, Lu Y1, Barkun A2, Martel M2, Moses P3
1McGill University, Montreal, QC, Canada, 2McGill University Health Center, Montreal, QC, Canada, 3University of Vermont, Burlington, VT, USA

PCN93
F9
A COST EFFECTIVENESS ANALYSIS OF 4 CHEMOTHERAPY REGIMENS IN THE TREATMENT OF PLATINUM SENSITIVE RECURRENT EPITHELIAL OVARIAN CARCINOMA
Burbano-Levy X1, Schroeder ED2, Diaz JP2
1Zilonis Health, Boca Raton, FL, USA, 2University of Miami, Miami, FL, USA

PCN94
F10
MOBILIZING AUTOLOGOUS HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MYELOMA: A ECONOMIC COMPARISON OF 4 COMMON MOBILIZATION STRATEGIES
Tay J, Sheppard D, Bredeson C, Allan D, Coyle D
University of Ottawa, Ottawa, ON, Canada

PCN95
F11
BRAF TARGETED THERAPIES FOR THE TREATMENT OF METASTATIC MELANOMA: A COST-EFFECTIVENESS ANALYSIS
Shih V1, ten Ham RM2, Bui CT1, Tran DN1, Wilson LS3
1University of California, San Francisco, San Francisco, CA, USA, 2Utrecht University, Utrecht, The Netherlands, 3University of California San Francisco, San Francisco, CA, USA

PCN96
F12
COST-EFFECTIVENESS OF AFATINIB, ERLOTINIB, AND CISPLATIN/PEMETREXED FOR FIRST-LINE TREATMENT OF METASTATIC EGFR-MUTATION POSITIVE NON-SMALL CELL LUNG CANCER
Ting J1, Ho T1, Xiang P1, Abdel-Sattar M1, Sugay A1, Wilson LS2
1University of California: San Francisco, San Francisco, CA, USA, 2University of California San Francisco, San Francisco, CA, USA

PCN97
F13
COST-EFFECTIVENESS OF ARSENIC TRIOXIDE IN THE TREATMENT OF RELAPSED/REFRACTORY ACUTE PROMYELOCYTIC LYMPHOMA LEUKEMIA IN CANADA
Lachaine J1, Mathurin K1, Barakat S2
1University of Montreal, Montreal, QC, Canada, 2Lundbeck Canada, Montreal, QC, Canada

PCN98
F14
COST-EFFECTIVENESS ANALYSIS OF INNOVATION IN HEMATOLOGIC MALIGNANCIES
Lin P1, Winn A2, Parsons SK1, Neumann PJ1, Cohen JT3
1Tufts Medical Center, Boston, MA, USA, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA

PCN99
F15
COST-EFFECTIVENESS EVALUATION OF SUNITINIB AS FIRST-LINE TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA IN KAZAKHSTAN
Kostyuk A1, Nurgozhin T2, Mazhitov T3, Almadiyeva A3
1Kazakh Medical University for Continuing Education, Astana, Kazakhstan, 2Nazarbayev University, The Center for Life Sciences, Astana, Kazakhstan, 3Astana Medical University, Astana, Kazakhstan

PCN100
F16
COST EFFECTIVENESS ANALYSIS OF ADDING RADIATION THERAPY TO ANDROGEN DEPRIVATION THERAPIES IN MEN WITH LOCALLY ADVANCED PROSTATE CANCER IN THE U.S.A
Upadhyay N
University of Houston, HOUSTON, TX, USA

PCN101
G1
THE EFFECT OF HERD IMMUNITY IN DIFFERENT HUMAN PAPILLOMAVIRUS VACCINATION STRATEGIES: AN ECONOMIC EVALUATION OF THE BEST II STUDY
Haussler K1, Marcellusi A2, Mennini FS3, Favato G4, Picardo M5, Garganese G6, Bononi M7, Scambia G8, Capone A9, Baio G1
1University College London, London, UK, 2University of Rome “La Sapienza”, Italy, Rome, Italy, 3University of Rome “Tor Vergata”, Italy, Rome, Italy, 4Kingston University, Kingston, UK, Kingston, UK, 5San Gallicano Dermatological Institute (IRCCS), Rome, Italy, 6Catholic University, 7University of Rome, Rome, Italy, 8University of the Sacred Heart, Rome, Italy, 9Kingston University London, London, UK

PCN102
G2
COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE-RITUXIMAB TREATMENT COMPARED WITH FLUDARABINE-RITUXIMAB TREATMENT, IN PATIENTS WITH INDOLENT NON-HODGKIN'S LYMPHOMA IN COSTA RICA
Desanvicente-Celis Z1, Obando CA2, Chaves M2, Gonzalez L3, Muschett D1
1Janssen, Panama, Panama, 2Janssen, Panama City, Panama, 3Janssen, Raritan, NJ, USA

PCN103
G3
REANALYSIS OF COST-EFFECTIVENESS OF ABIRATERONE ACETATE AS SECOND LINE TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN JAPAN USING A JAPANESE CLAIM DATA SET
Shibahara H1, Shiroiwa T2, Tange C1, Nakamura K1, Ozono S3, Shimozuma K1
1Ritsumeikan University, Kusatsu, Japan, 2Okayama University Hospital, Okayama, Japan, 3Hamamatsu University, Hamamatsu, Japan

PCN104
G4
USE OF PSA SLOPE TO GUIDE ADJUVANT RADIOTHERAPY IN POST-PROSTATECTOMY PROSTATE CANCER HAS POTENTIAL TO BE COST EFFECTIVE
Reed SD1, Biehn Stewart S2, Scales CD2, Moul JW2
1Duke Clinical Research Institute, Durham, NC, USA, 2Duke University School of Medicine, Durham, NC, USA

PCN105
G5
COST-EFFECTIVENESS OF CETUXIMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN THE US
Ortendahl JD1, Bentley TG1, Anene AM1, Purdum AG2, Bolinder B2
1Partnership for Health Analytic Research, LLC, Beverly HIlls, CA, USA, 2Bristol-Myers Squibb, Plainsboro Township, NJ, USA

PCN106
G6
COST-EFFECTIVENESS OF PROPHYLACTIC USE OF FILGRASTIM IN ADULTS WITH ACUTE LEUKEMIA LYMPHOBLASTIC COLOMBIA
Casadiego EJ1, Diaz Rojas JA2, Bermudez C3, Prieto-Martinez V4, Urrego Novoa JR5
1CENTRO DERMATOLOGICO, Bogota, Cundinamarca, Colombia, 2Universidad Nacional de Colombia, Bogota D,C., Colombia, 3Instituto Nacional de Cancerología, Bogotá, Cundinamarca, Colombia, 4Universidad Nacional de Colombia, Bogotá, Colombia, 5Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá, Colombia

PCN107
G7
COST-EFFECTIVENESS OF FULL-FIELD DIGITAL MAMMOGRAPHY VS. SCREEN-FILM MAMMOGRAPHY IN BREAST CANCER SCREENING
Hipolito C, Gallegos V, Hernandez E
National Center for Health Technology Excellence, Mexico City, Mexico

PCN108
G8
PARAMETER VALUES ASSOCIATED WITH THE DEVELOPMENT OF A GLOBAL ECONOMIC MODEL TO VALUE COMPANION DIAGNOSTICS IN ADVANCED/METASTATIC CANCER TREATMENT
Lachaine J, Mathurin K, Beauchemin C
University of Montreal, Montreal, QC, Canada

PCN109
G9
CAN NEXT GENERATION SEQUENCING SAVE LIVES AND PROVIDE A GOOD ECONOMIC VALUE IN COLON CANCER PREVENTION?
Gallego CJ1, Shirts B1, Garrison L2, Jarvik G1, Veenstra DL3
1University of Washington, Seattle, WA, USA, 2University of Washington School of Pharmacy, Seattle, WA, USA, 3School of Pharmacy, University of Washington, Seattle, WA, USA

PCN110
G10
AN OUTCOMES MODEL FOR HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER TREATMENT OPTIONS
Ramamohan V1, Mladsi DM2, Boey W3, Pozzi R4, Kaye JA5
1RTI Health Solutions, Durham, NC, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Telormedix, Bioggio, Switzerland, 4Telormedix SA, Bioggio, Switzerland, 5RTI Health Solutions, Waltham, MA, USA

PCN111
G11
COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN COMBINATION WITH PC REGIMEN VERSUS PC REGIMEN IN NON-SMALL CELL LUNG CANCER TREATMENT
Nguyen TT, Tran TT
University of Medicine and Pharmacy in HCMC, Ho Chi Minh City, Vietnam

PCN112
G12
ECONOMIC EVALUATION OF FULVESTRANT 500MG FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER WHO HAVE PROGRESSED ON ENDOCRINE THERAPY
Polanco AC1, Salazar A1, Soto H2, Pizarro M3
1AstraZeneca, Tlalpan, Mexico, 2Health Solutions Consulting, D. F., Mexico, 3Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico

PCN113
G13
ASSESSMENT COST-EFFECTIVENESS OF PEGFILGRASTIM AND FILGRASTIM IN PEDIATRIC PATIENTS WITH SOLID TUMORS
Medina Barajas FP1, Sánchez Zubieta F2, Islas Carbajal MC3, Pardo Zepeda M1, Ramírez Urenda X2, Rincón Sánchez AR3
1Universidad de Guadalajara, Guadalajara, Mexico, 2Hospital Civil de Guadalajara, Guadalajara, Mexico, 3CUCS, Universidad de Guadalajara, Guadalajara, Mexico

PCN114
G14
A RANDOMIZED CLINICAL STUDY TO EVALUATE EFFECTS OF EICOSAPENTAENOIC ACID ENRICHED ORAL NUTRITIONAL SUPPLEMENT ALONG WITH RADIO-CHEMOTHERAPY IN PATIENTS WITH COLORECTAL CARCINOMA: A COST-EFFECTIVENESS ANALYSIS
Berktas M1, Kilic D2, Ozcagli TG3, Sencan N1
1Yeditepe University PEPIRC, Istanbul, Turkey, 2Gazi University, Ankara, Turkey, 3Abbott Nutrition, Istanbul, Turkey

PCN115
G15
PROJECTING THE POTENTIAL PUBLIC HEALTH IMPACT OF A 9-VALENT HPV VACCINE IN JAPAN
Weiss T1, Pillsbury M2, Abe M3, Sato M3, Yamabe K4
1Merck & Co, Inc., West Point, PA, USA, 2Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA, 3MSD.K.K. Japan, Tokyo, Japan, 4HTA and Public Policy Project, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan

PCN116
G16
COMPARING FIVE ALTERNATIVE METHODS OF BREAST RECONSTRUCTION SURGERY: A COST-EFFECTIVENESS ANALYSIS
Padula WV1, Grover R2, Van Vliet M3, Ridgway EB4
1University of Chicago, Chicago, IL, USA, 2Dartmouth College, Hanover, NH, USA, 3University of Southern California, Los Angeles, CA, USA, 4Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA

PCN117
G17
A HEALTH TECHNOLOGY ASSESSMENT OF A PROPOSED BIOSIMILAR FOR THE TREATMENT OF CHEMOTHERAPY INDUCED FEBRILE NEUTROPENIA: A U.S. PAYER PERSPECTIVE
Vaidya N1, Cosler L2
1University of Colorado Denver, Aurora, CO, USA, 2Albany College of Pharmacy and Health Sciences, Albany, NY, USA

PCN118
WITHDRAWN

PCN119
G18
COST-UTILITY ANALYSIS OF DABRAFENIB/TRAMETINIB COMBINATION (D+T) FOR BRAFV600 MUTATION-POSITIVE METASTATIC MELANOMA (MM) FROM THE UNITED KINGDOM (UK) NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE
Delea TE1, Amdahl J1, Wang A1, Amonkar M2, Smith HW3, Balaratnam S3, Stapelkamp C4
1Policy Analysis Inc. (PAI), Brookline, MA, USA, 2GlaxoSmithKline, Collegeville, PA, USA, 3GlaxoSmithKline, London, UK, 4GlaxoSmithKline, Uxbridge, UK

PCN120
G19
COST-UTILITY ANALYSIS OF CYSTECTOMY VS. CHEMO-RADIATION FOR TREATMENT OF MUSCLE-INVASIVE BLADDER CANCER IN THE ELDERLY
Smith AB1, Borse MS2, Modebe NC1, Nielsen ME1, Pruthi RS1, Johnson DC1, Wallen EM1, Woods MM1, Milowsky MI3, Chen RC4, Biddle AK5
1University of North Carolina, Chapel Hill, NC, USA, 2, Chapel Hill, NC, USA, 3University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4University of North Carolina at Chapel Hill, School of Medicine, Department of Radiation Oncology and Urology, Chapel Hill, NC, USA, 5University of North Carolina at Chapel Hill, Gillings School of Global Public Health, Chapel Hill, NC, USA

PCN121
G20
COST EFFECTIVENESS OF DIFFERENT DIGITAL MAMMOGRAPHY SCREENING SCENARIOS FOR BREAST CANCER IN THE CANADIAN CONTEXT
Mittmann N1, Stout N2, Tosteson A3, Yaffe M4
1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2Harvard University, Boston, MA, USA, 3Dartmouth, Lebanon, NH, USA, 4Physical Sciences Program, Sunnybrook Research Institute and Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada

PCN122
G21
VALUE OF INNOVATION IN LEUKEMIA, LYMPHOMA, AND MYELOMA: A SYSTEMATIC REVIEW
Saret CJ1, Winn A2, Shah G1, Parsons SK1, Lin P1, Cohen JT3, Neumann PJ1
1Tufts Medical Center, Boston, MA, USA, 2University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 3Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA

PCN123
H1
COST-EFFECTIVENESS OF USING A PROGNOSTIC TEST TO GUIDE TREATMENT DECISIONS IN EARLY STAGE NON-SMALL CELL LUNG CANCER (NSCLC)
Stenehjem D1, Bellows BK1, Kaldate RR2, Jones J2, Siebert U3, Brixner D1
1University of Utah, Salt Lake City, UT, USA, 2Myriad Genetic Laboratories, Inc., Salt Lake City, UT, USA, 3Medical Informatics and Technology, and Director of the Division for Health Technology Assessment and Bioinformatics, ONCOTYROL, Hall i. T, Austria

PCN124
H2
ESTIMATION OF THE QUALITY ADJUSTED PROGRESSION FREE SURVIVAL OF THE TREATMENT ARMS OF THE BOLERO-2 TRIAL
Ali AA, Adunlin G, Tawk R, Diaby V
Florida A&M University, Tallahassee, FL, USA

PCN125
WITHDRAWN

PCN126
H3
COST-UTILITY ANALYSIS OF ENZALUTAMIDE FOR PATIENTS WITH PREVIOUSLY TREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Vicente C1, Babashov V1, Husein F2, Saad F3, Naidoo S4, Holmstrom S5
1PIVINA Consulting Inc., Mississauga, ON, Canada, 2Astellas Pharma Canada Inc, 3CHUM, Montreal, QC, Canada, 4Astellas Pharma Europe Ltd, Chertsey, UK, 5HEOR, Astellas Pharma Global Development, Leiden, The Netherlands

PCN127
H4
COST-UTILITY ANALYSIS OF NEWER HER2- TESTING TECHNOLOGIES TO TARGET TRASTUZUMAB IN THE ADJUVANT BREAST CANCER SETTING
Ferrusi IL1, Kulin NA2, Goeree R1, Leighl N3, Pullenayegum EM4, Phillips K5, Marshall D2
1McMaster University, Hamilton, ON, Canada, 2University of Calgary, Calgary, AB, Canada, 3Ontario Cancer Institute, Toronto, ON, Canada, 4Hospital for Sick Children, Toronto, ON, Canada, 5University of California, San Francisco, San Francisco, CA, USA

PCN128
H5
THE COST-EFFECTIVENESS OF 2ND LINE CRIZOTINIB IN EML4-ALK REARRANGED ADVANCED NSCLC IN ONTARIO
Djalalov S1, Graham DM2, Beca J1, Hoch JS3, Tsao M4, Cutz J5, Leighl N4
1St. Michael's Hospital, Toronto, ON, Canada, 2Princess Margaret Hospital, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4Ontario Cancer Institute, Toronto, ON, Canada, 5McMaster University, Hamilton, ON, Canada

PCN129
H6
COMPARATIVE COSTS AND EFFECTIVENESS OF MINDFULNESS-BASED ART THERAPY TO USUAL SUPPORT FOR WOMEN WITH CANCER: RESULTS FROM A RANDOMIZED CLINICAL TRIAL
Pizzi LT1, Morlino AM1, Kash KM2, Newberg A1, Matthews MJ1, Monti D1
1Thomas Jefferson University, Philadelphia, PA, USA, 2KM Behavioral Consulting, Spring Hill, FL, USA

PCN130
H7
COST-EFFECTIVENESS OF TARGETED THERAPEUTICS IN METASTATIC RENAL CELL CANCER SEEN FROM TWO DIFFERENT ECONOMIC PERSPECTIVES
Mihajlović J, Postma MJ
University of Groningen, Groningen, The Netherlands

PCN131
H8
COST-EFFECTIVENESS OF PAZOPANIB VERSUS SUNITINIB IN EGYPTIAN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA FROM THE HEALTH INSURANCE PERSPECTIVE: A MARKOV MODEL
Elsisi G1, Hassouna A2, Abu Taleb A2, Elmahdawy M3, Ibrahim S2
1Ministry of Health, Faculty of Pharmacy Helwan University, Cairo, Egypt, 2Central Administration for Pharmaceutical Affairs, Cairo, Egypt, 3Ministry of Health, Cairo, Egypt

PCN132
H9
COST-UTILITY ANALYSIS OF COFFEE CONSUMPTION FOR PREVENTION OF CHRONIC DISEASE AND CANCER IN THE UNITED STATES
O'Day K, Campbell CM, Popelar BV
Xcenda, LLC, Palm Harbor, FL, USA

PCN133
H10
COMPARE DEMOGRAPHIC AND CLINICAL CHARACTERISTICS AMONG COLORECTAL CANCER PATIENTS WITH A DIFFERENT NUMBER OF TREATMENT LINES IN THE U.S. VETERANS HEALTH ADMINISTRATION
Seal BS1, Xie L2, Rietschel P3, Baser O4
1Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, 2STATinMED Research, Ann Arbor, MI, USA, 3Bayer HealthCare Pharmaceuticals, Inc., Whippany, NJ, USA, 4STATinMED Research and The University of Michigan, Ann Arbor, MI, USA

PCN134
H11
COST-UTILITY ANALYSIS OF PRACTICE DEVIATIONS FROM GUIDELINES IN HER2-TARGETED TESTING AND TREATMENT FOR BREAST CANCER
Ferrusi IL1, Kulin NA2, Goeree R1, Leighl N3, Pullenayegum EM4, Phillips K5, Marshall D2
1McMaster University, Hamilton, ON, Canada, 2University of Calgary, Calgary, AB, Canada, 3Ontario Cancer Institute, Toronto, ON, Canada, 4Hospital for Sick Children, Toronto, ON, Canada, 5University of California, San Francisco, San Francisco, CA, USA

PCN135
H12
RESOURCE USE AND COSTS ASSOCIATED WITH THE TREATMENT OF ADVERSE EVENTS IN CHRONIC MYELOID LEUKEMIA (CML) BRAZILIAN PATIENTS
Alves MR1, Boquimpani C2
1Novartis Pharmaceuticals, São Paulo, Brazil, 2HEMORIO, Rio de Janeiro, Brazil

PCN136
H13
HEALTHCARE COST AND UTILIZATION AMONG PATIENTS TREATED WITH STIVARGA
Chastek B1, Seal BS2, Rietschel P2
1OptumInsight, Eden Prairie, MN, USA, 2Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA

CANCER - Patient-Reported Outcomes & Patient Preference Studies
PCN137
H14
TREATMENT PATTERNS AND PERSISTENCE AMONG PATIENTS TREATED WITH STIVARGA
Chastek B1, Seal BS2, Rietschel P2
1OptumInsight, Eden Prairie, MN, USA, 2Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA

PCN138
H15
COMPARISON OF ADHERENCE RATES BETWEEN ORAL CAPECITABINE AND INTRAVENOUS CHEMOTHERAPY REGIMENS TO TREAT METASTATIC COLON CANCER
Seal BS1, Anderson S2, Cameron J2, Shermock KM3
1Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ, USA, 2Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA, 3The Johns Hopkins Medical Institutions, Baltimore, MD, USA

PCN139
H16
THE ASSOCIATION BETWEEN NON-ADHERENCE AND QUALITY OF LIFE AMONG WOMEN WITH METASTATIC BREAST CANCER
DiBonaventura M1, Copher R2, Basurto E1, Faria C2, Lorenzo R1
1Kantar Health, New York, NY, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA

PCN140
H17
HEALTH STATE UTILITIES FOR CHRONIC LYMPHOCYTIC LEUKEMIA
Shingler SL1, Kosmas CE1, Samanta K2, Wiesner C3, Lloyd AJ1
1ICON Patient Reported Outcomes, Oxford, UK, 2Roche Products Limited, Welwyn Garden City, UK, 3Genentech Inc., South San Francisco, CA, USA

PCN141
H18
A SYSTEMATIC REVIEW OF HEALTH-STATE UTILITY VALUES IN ADVANCED GASTRIC, OESOPHAGEAL, OR GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA
Cuyun Carter G1, King DT2, Mitchell SA2, Hess LM1, Taipale K3, Kiiskinen U3, Rajan N4, Novick D5, Liepa AM1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Abacus International, Bicester, UK, 3Oy Eli Lilly Finland Ab, Helsinki, Finland, 4Eli Lilly Australia Pty Limited, West Ryde, Australia, 5Eli Lilly and Company, Windlesham, UK

PCN142
H19
QUALITY OF LIFE OUTCOMES OF THE US CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
Kuo K1, Stenehjem D1, Kluibenschaedl M2, Rochau U3, Brixner D1
1University of Utah, Salt Lake City, UT, USA, 2UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i. T., Austria, 3UMIT - University for Health Sciences, Medical Informatics and Technology/ ONCOTYROL - Center for Personalized Cancer Medicine, Hall in Tyrol/ Innsbruck, Austria

PCN143
H20
SANDOSTATIN LAR PATIENT JOURNEY
MacDonald C1, Kay S2, Saldanha K1, Bassevitch Y1, Rice T2
1Tendler Group, Montreal, QC, Canada, 2Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada

PCN144
H21
RELATIVE INFLUENCE OF FACTORS DETERMINING A WOMAN'S PREFERENCE FOR TREATMENT OPTIONS IN OVARIAN CANCER: A DISCRETE CHOICE EXPERIMENT
Havrilesky LJ1, Secord AA1, Ehrisman J1, Berchuck A1, Valea FA1, Lee PS1, Cella D2, Weinfurt K3, Abernethy AP3, Reed SD3
1Duke University, Durham, NC, USA, 2Northwestern University, Chicago, IL, USA, 3Duke Clinical Research Institute and Duke Cancer Institute, Durham, NC, USA

PCN145
I1
PHYSICIANS' PREFERENCES FOR BONE METASTASES TREATMENTS IN CANADA
Hauber AB1, Arellano J2, Qian Y2, Habib M3, Posner J1, Mohamed A1, González JM1
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3Amgen Canada Inc., Mississauga, ON, Canada

PCN146
I2
QUALITATIVE ASSESSMENT OF MULTIPLE MYELOMA SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE IN RELAPSED/REFRACTORY PATIENTS AND COMPARISON TO THE EORTC QLQ-C30 AND MY-20, FACT-MM, AND MDASI-MM
Trask PC1, Taylor F2, Shields A3, Mehta J1, Foley C2, Olude O2, Lamoureux R2, Iovin R2, Hsu K1
1Sanofi, Cambridge, MA, USA, 2Adelphi Values USA, Boston, MA, USA, 3Adelphi Values, Boston, MA, USA

PCN147
I3
RECRUITING AND INTERVIEWING NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS FOR QUALITATIVE STUDY PARTICIPATION VIA AN INTERNET-BASED DIGITAL PATIENT COMMUNITY
Tomaszewski EL1, Krupnick R2, Moïse P3, Downing J4, Holmstrom S5
1Quintiles, Pittsburgh, PA, USA, 2Quintiles Consulting, Cambridge, MA, USA, 3Quintiles Consulting Europe, Levallois-Perret, France, 4Quintiles, Durham, North Carolina, USA, 5HEOR, Astellas Pharma Global Development, Leiden, The Netherlands

PCN148
I4
: IDENTIFYING SYMPTOMS AND IMPACTS EXPERIENCED BY MEN WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Moïse P1, Tomaszewski EL2, Krupnick R3, Baskin-Bey E4, Meyer M3, Holmstrom S5
1Quintiles Consulting Europe, Levallois-Perret, France, 2Quintiles, Pittsburgh, PA, USA, 3Quintiles Consulting, Cambridge, MA, USA, 4Astellas Pharma Global Development, Leiden, The Netherlands, 5HEOR, Astellas Pharma Global Development, Leiden, The Netherlands

PCN149
I5
ASSESSMENT OF RESPONSE SHIFT AND TRUE CHANGE USING STRUCTURAL EQUATION MODELING FOR HEALTH–RELATED QUALITY-OF-LIFE SCORES IN PATIENTS WITH BREAST CANCER AFTER SURGERY
Nakamura K1, Shimozuma K1, Suzukamo Y2, Taira N3, Shiroiwa T3, Shibahara H1, Saito S4
1Ritsumeikan University, Kusatsu, Japan, 2Tohoku Universitiy, Seidai, Japan, 3Okayama University Hospital, Okayama, Japan, 4Okayama University, Okayama, Japan

PCN150
WITHDRAWN

PCN151
I6
PATIENT REPORTED OUTCOMES IN CASTRATION-RESISTANT PROSTATE CANCER
Aggarwal S, Segal J
Novel Health Strategies, Bethesda, MD, USA

PCN152
I7
IMPACT OF COLORECTAL CANCER ON ACTIVITIES OF DAILY LIVING AND DEPRESSION RISK AMONG OLDER AMERICANS
Quach C, Sanoff HK, Williams GR, Lyons JC, Reeve BB
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PCN153
WITHDRAWN

PCN154
I8
THE REAL IMPACT OF QUALITY OF LIFE (QOL) ENDPOINTS ON MARKET ACCESS DECISIONS ACROSS MARKETS – A CASE STUDY OF ONCOLOGY PRODUCTS
Gardiner RB1, Sealey S1, Edathodu A1, Mukku SR2
1Access Partnership, London, UK, 2The Access Partnership, London, UK

PCN155
I9
IMPROVED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH OFATUMUMAB PLUS CHLORAMBUCIL OR CHLORAMBUCIL
Hillmen P1, Haiderali A2, Chang C3
1St. James University Hospital, Leeds, UK, 2GlaxoSmithKline, Collegeville, PA, USA, 3GlaxoSmithKline, Research Triangle Park, NC, USA

PCN156
I10
THE ASSOCIATION OF COMORBID ANXIETY AND MOOD DISORDERS WITH HEALTH-RELATED QUALITY OF LIFE AMONG CANCER SURVIVORS
Park C, Kim G, Jiang S, Lawson KA
The University of Texas at Austin, Austin, TX, USA

PCN157
I11
HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH METASTATIC, RELAPSED, OR INOPERABLE SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN INDIA
Patil V1, Prabhash K1, Marfatia S2, Patel M2, Gupta K2, Kamble S2
1Tata Memorial Hospital, Mumbai, India, 2pharmEDGE, Mumbai, India

PCN158
I12
HEALTH RELATED QUALITY OF LIFE AMONG PATIENTS DIAGNOSED WITH ADVANCED NON SMALL CELL LUNG CANCER IN INDIA
Prabhash K1, Marfatia S2, Patel M2, Kamble S2
1Tata Memorial Hospital, Mumbai, India, 2pharmEDGE, Mumbai, India

PCN159
I13
THE ASSOCIATION OF CHEMOTHERAPY VERSUS HORMONAL THERAPY AND HEALTH OUTCOMES AMONG PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE METASTATIC BREAST CANCER: EXPERIENCE FROM THE PATIENT PERSPECTIVE
Jerusalem G1, Gupta S2, Zhang J3
1Centre Hospitalier Universitaire du Sart Tilman Liège, Liege, Belgium, 2Kantar Health, Princeton, NJ, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

CANCER - Health Care Use & Policy Studies
PCN160
I14
COST OF DISCORDANT DIAGNOSES IN SARCOMA, GIST, AND DESMOID TUMORS IN FRANCE: RESULTS FROM THE RREPS (RESEAU DE REFERENCE EN PATHOLOGIE DES SARCOMES) NETWORK
Perrier L1, Rascle P1, Ray-Coquard I1, Bui Nguyen B2, Morelle M1, Ranchère Vince D1, Terrier P3, Neuville A2, Decouvelaere A1, Le Cesne A3, Gomez F1, de la Fouchardière C1, Meeus P1, Trédan O1, Pérol M1, Fayette J1, Neidhardt E1, Biron P1, Boyle HJ1, Marec-Bérard P4, Farsi F5, Ducimetière F1, Blay J1, Coindre J2
1Cancer Centre Léon Bérard, Lyon, France, 2Institut Bergonié, Bordeaux, France, 3Institut Gustave Roussy, Villejuif, France, 4IHOP, Lyon, France, 5Regional oncology network Réseau Espace Santé Cancer, Lyon, France

PCN161
I15
SYSTEMATIC REVIEW AND ASSESSMENT OF PATIENTS WITH RELAPSED OR REFRACTORY CLL/SLL AFTER FIRST-LINE THERAPY
Gaudig M1, Erhardt W2, Kempel A3
1Janssen EMEA, Neuss, Germany, 2Janssen-Cilag GmbH, Neuss, Germany, 3Pharmametrics GmbH, Freiburg, Germany

PCN162
I16
PSA MONITORING AND RESULTS AMONG MEN WITH NON-METASTATIC PROSTATE CANCER
Wilson KL, Foley KA
Truven Health Analytics, Bethesda, MD, USA

PCN163
I17
RESOURCE USE ASSOCIATED WITH PATIENTS WITH THYROID CANCER IN A US INSURED POPULATION
Hirst C1, Kern DM2, Zhou S2, Tunceli O2, Tchinou C1, Prahladen M1, Ryan J1
1AstraZeneca, Macclesfield, UK, 2HealthCore, Inc., Wilmington, DE, USA

PCN164
I18
SYSTEMATIC REVIEW AND ASSESSMENT OF OUTCOMES IN PATIENTS WITH THE RARE DISEASE OF MANTLE CELL LYMPHOMA (MCL)
Gaudig M1, Erhardt W2, Kempel A3
1Janssen EMEA, Neuss, Germany, 2Janssen-Cilag GmbH, Neuss, Germany, 3Pharmametrics GmbH, Freiburg, Germany

PCN165
I19
EFFECTS OF NEWLY DIAGNOSED CANCER ON MEDICATION MANAGEMENT OF PREVALENT DIABETES
Erten MZ1, Stuart B2, Davidoff AJ3
1University of Vermont - College of Medicine, Burlington, VT, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA, 3Agency for Healthcare Research and Quality, Rockville, MD, USA

PCN166
I20
REGIONAL VARIATIONS IN HEALTHCARE EXPENDITURES AMONG MEDICARE BENEFICIARIES WITH COLORECTAL CANCER
Rane PB1, Madhavan S1, Sambamoorthi U1, Kalidindi S1, Kurian S2, Pan X1
1West Virginia University School of Pharmacy, Morgantown, WV, USA, 2West Virginia University School of Medicine, Morgantown, WV, USA

PCN167
I21
TREATMENT AND SURVIVAL PATTERNS AMONG ELDERLY MEDICARE BENEFICIARIES WITH COLORECTAL CANCER: A COMPARATIVE ANALYSIS BETWEEN A RURAL STATE CANCER REGISTRY AND NATIONAL DATA
Rane PB1, Madhavan S1, Sambamoorthi U1, Kalidindi S1, Kurian S2, Pan X1
1West Virginia University School of Pharmacy, Morgantown, WV, USA, 2West Virginia University School of Medicine, Morgantown, WV, USA

PCN168
J1
FIRST TWO YEARS OF HEALTH SYSTEM RESOURCES AND COSTS FOLLOWING A STAGE DEFINED BREAST CANCER DIAGNOSIS: A POPULATION BASED APPROACH
Mittmann N1, Porter J1, Rangrej J1, Seung SJ1, Saskin R1, Cheung M1, Leighl N2, Hoch J3, Trudeau M1, Evans W4, Dainty KN5, DeAngelis C1, Earle CC6
1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2Ontario Cancer Institute, Toronto, ON, Canada, 3Cancer Care Ontario, Toronto, ON, Canada, 4McMaster University, Hamilton, ON, Canada, 5St. Michael's Hospital, Toronto, ON, Canada, 6Cancer Care Ontario / Institute for Cancer Research, Toronto, ON, Canada

PCN169
J2
TREATMENT PATTERNS AMONG PATIENTS WITH BREAST CANCER: DOES INSURANCE STATUS MATTER?
Jiao X, Mu G, Cai Y
IMS Health, Plymouth Meeting, PA, USA

PCN170
WITHDRAWN

PCN171
J3
EFFICACY, SAFETY AND COST-EFFECTIVENESS OF TRASTUZUMAB IN METASTATIC GASTRIC CANCER TREATMENT IN CHINA
Sun W1, Chen W2
1Fudan University, Shanghai, China, 2Center for Pharmacoeconomic Research and Evaluation, School of Public Health, Fudan University, Shanghai, China

PCN172
J4
A CALL TO MONITOR DRUG SHORTAGES AND THE ROLE OF MARKET ATTRACTIVENESS IN EUROPEAN COUNTRIES
Pauwels K, Huys I, Casteels M, Simoens S
KU Leuven, Leuven, Belgium

PCN173
J5
DOWNFALLS OF THE FDA ACCELERATED APPROVAL PATHWAY – STRINGENT CONTROLS MUST BE INVOKED TO ENSURE PROMPT SUBMISSION OF FOLLOW-UP CONFIRMATORY TRIAL DATA
Macaulay R
HERON Commercialization, London, UK

PCN174
J6
EVIDENCE FOR A LOWERED THRESHOLD FOR FDA APPROVAL OF ONCOLOGICS BASED ON SINGLE-ARM PHASE II DATA, COMPARED TO THE EMA
Macaulay R
HERON Commercialization, London, UK

PCN175
J7
A RETROSPECTIVE STUDY OF PATIENTS OUT-OF-POCKET COSTS FOR ORAL ONCOLOGY MEDICATIONS FOR MULTIPLE MYELOMA
Rice G
Diplomat, Flint, MI, USA

PCN176
J8
ASSESSMENT OF IMAGING UTILIZATION AND TREATMENT PATTERNS FOR HEAD AND NECK CANCER PATIENTS IN THE UNITED STATES
Bresnahan BW1, Alfonso-Cristancho R2, He H2, Mendez E1, Goulart B1, Parvathaneni U1, Kramer B2, Anzai Y1
1University of Washington, Seattle, WA, USA, 2Department of Surgery, University of Washington, Seattle, WA, USA

PCN177
J9
DESCRIPTIVE ANALYSIS OF PATIENTS INITIATING REGORAFENIB THERAPY
Slabaugh SL1, Louder A1, Michels S1, Hopson SD1, Rietschel P2, Seal B3
1Comprehensive Health Insights, Inc., Louisville, KY, USA, 2Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ, USA, 3Bayer HealthCare Pharmaceuticals, Inc., White House Station, NJ, USA

PCN178
J10
USE OF BONE-MODIFYING AGENTS FOLLOWING ANDROGEN DEPRIVATION THERAPY FOR MEDICARE NON-METASTATIC PROSTATE CANCER PATIENTS
Yong C1, Onukwugha E1, Mullins CD1, Zuckerman IH1, Hussain A2, Naslund M2
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland School of Medicine, Baltimore, MD, USA

PCN179
J11
THE DOWNWARD TREND IN ONCOLOGY DRUG PRICING, SPEED TO MARKET AND ACCESS
Colasante W1, Alexander R1, Clark J1, Hickson S1, Li X2
1IMS Consulting Group, Cambridge, UK, 2University of Cambridge, Cambridge, UK

PCN180
J12
FACTORS ASSOCIATED WITH REPEAT MAMMOGRAPHY SCREENING IN THE MEDICAID POPULATION
Mahabaleshwarkar R1, Khanna R1, Banahan BF1, West-Strum D1, Yang Y1, Hallam J2
1University of Mississippi, University, MS, USA, 2Kent State University, Kent, OH, USA

PCN181
J13
ONCOLOGY PRICING TRENDS IN THE UNITED STATES AND THE UNITED KINGDOM (2011-2013)
Aggarwal S1, Topaloglu H2
1Novel Health Strategies, Bethesda, MD, USA, 2NOVEL Health Strategies, Chevy Chase, MD, USA

PCN182
J14
AN APPRAISAL OF PCODR'S DECISIONS AND INFLUENCE OVER THE LAST 3 YEARS
Joinnides M1, Beckerman R2
1CBPartners, San Francisco, CA, USA, 2CBPartners, New York, NY, USA

PCN183
J15
EFFECTS OF THE PRIMARY PAYER TYPE AND RACE/ETHNICITY ON PROSTATE CANCER SCREENING PRACTICES DURING PREVENTIVE HEALTH EXAMS IN US AMBULATORY CARE SETTINGS
Jayasekera J, Onukwugha E
University of Maryland School of Pharmacy, Baltimore, MD, USA

PCN184
J16
CANCER CARE COSTS TREND IN THE US: FINDINGS FROM THE MEDICAL EXPENDITURE PANEL SURVEY 2008-2011
Haider MR1, Qureshi Z1, Salloum R1, Heidari K2, Xirasagar S1, Bennett C1, Khan MM1
1University of South Carolina, Columbia, SC, USA, 2Department of Health and Environmental Control, Columbia, SC, USA

PCN185
WITHDRAWN

PCN186
WITHDRAWN

PCN187
WITHDRAWN

PCN188
J17
AN ONLINE PATIENT-ORIENTED RADIATION RISK ASSESSMENT TOOL TO PROJECT CANCER RISK FOLLOWING EXPOSURE TO LOW–IONIZING RADIATION IN CANADA
Zowall H, Brewer C, Deutsch A
Zowall Consulting Inc., Westmount, QC, Canada

PCN189
J18
REIMBURSEMENT RECOMMENDATIONS FOR CANCER PRODUCTS WITHOUT STATISTICALLY SIGNIFICANT OVERALL SURVIVAL DATA: A REVIEW OF CANADIAN PCODR DECISIONS
Heyland K1, Samjoo IA2, Grima DT1
1Cornerstone Research Group, Burlington, ON, Canada, 2Cornerstone Research Group Inc., Burlington, ON, Canada

PCN190
J19
INSIGHTS INTO THE PAN-CANADIAN ONCOLOGY DRUG REVEW RECOMMENDATIONS - THREE YEARS AFTER ITS INCEPTION
Samjoo IA1, Grima DT2
1Cornerstone Research Group Inc., Burlington, ON, Canada, 2Cornerstone Research Group, Burlington, ON, Canada

PCN191
J20
LESSONS FOR ADAPTIVE LICENSING: ANALYSIS OF CONDITIONALLY APPROVED EMA COMPOUNDS, THEIR REIMBURSEMENT STATUS AND REGULATORY/REIMBURSEMENT DATA REQUIREMENTS
Spearpoint PA, Yip C, Zhang W
Pope woodhead and Associates, Cambridgeshire, UK

PCN192
J21
CORRELATION OF HTA DECISION OUTCOMES IN FRANCE AND GERMANY
Sun D1, Beckerman R2, Bustamante MM2
1CBPartners, New York City, NY, USA, 2CBPartners, New York, NY, USA

PCN193
K1
COMPARISON OF ONCOLOGY THERAPY REIMBURSEMENT RECOMMENDATIONS MADE BY HEALTH TECHNOLOGY ASSESSMENT AGENCIES IN AUSTRALIA, CANADA, SWEDEN, AND UNITED KINGDOM
Samjoo IA1, Grima DT2
1Cornerstone Research Group Inc., Burlington, ON, Canada, 2Cornerstone Research Group, Burlington, ON, Canada

PCN194
K2
THE CANCER LANDSCAPE IN BRAZIL: A RETROSPECTIVE ANALYSIS OF BRAZILIAN NATIONAL INSTITUTE OF CANCER PATIENT REGISTRY DATABASE (RHC-INCA)
Tsuchiya CT, Maximo MF, Gonçalves TM
Roche Brazil, São Paulo, Brazil

PCN195
K3
NADIA® PSA SLOPE IMPACTS UROLOGISTS' RECOMMENDATIONS FOR ADJUVANT RADIOTHERAPY FOR PROSTATE CANCER PATIENTS WITH HIGH-RISK PATHOLOGY FOLLOWING RADICAL PROSTATECTOMY
Reynolds MA1, Moul JW2, McDermed J1
1Beckman Coulter, Carlsbad, CA, USA, 2Duke University School of Medicine, Durham, NC, USA

PCN196
K4
FACTORS INFLUENCING USE OF GENE EXPRESSION PROFILING BY PHYSICIANS FOR BREAST CANCER TREATMENT RECOMMENDATIONS
Issa AM1, Patil D2
1University of the Sciences in Philadelphia, Philadelphia, PA, USA, 2, Philadelphia, PA, USA

PCN197
K5
TREATMENT PATTERNS AND BASELINE CHARACTERISTICS OF A PROSPECTIVE COHORT OF PATIENTS WITH ADVANCED NSCLC TREATED IN REAL WORLD COMMUNITY ONCOLOGY SETTINGS
Walker MS1, Ravelo A2, Miller PJ1
1ACORN Research, LLC, Memphis, TN, USA, 2Genentech, Inc, South San Francisco, CA, USA

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.